Summit's ivonescimab data has sparked interest in BioNTech's BNT327, and its potential to follow a similar path and gain value. Goldman incorporates risk-adjusted revenue forecasts that currently ...
Analysts' ratings for BioNTech (NASDAQ:BNTX) over the last quarter vary from bullish to bearish, as provided by 17 analysts. The following table encapsulates their recent ratings, offering a ...
BioNTech already owned part of InstaDeep as it backed the company's $100 million Series B last year, but will take 100% control of the company if the merger goes ahead as planned.
mRNA specialist BioNTech has chalked up an important win in its cancer pipeline, showing efficacy with its BNT111 vaccine candidate in a phase 2 trial in advanced melanoma. The study is looking at ...
Auf einen Blick zu BioNTech: - Umsatz in den ersten 9 Monaten 2024 bei 1,56 Milliarden Euro - Nettoverlust von 924,8 Millionen Euro, bedingt durch hohe F&E-Kosten - Umsatzprognose für 2024 am ...
I'm expecting to pass my final exam in July 2025. As much as I would like to stay at BioNTech, the current status of the company does not anticipate the recruitment of trainees for now. The situation ...
BioNTech (ADRs) News: auf dieser Seite finden Sie alle BioNTech (ADRs) News und Nachrichten zur BioNTech (ADRs) Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch BioNTech (ADRs ...
Bats 106,11 USD 106,32 USD-0,21-0,20% 105,58 - 108,90 31.309 23:14:25 12.11.2024 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback